These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 37306560)
1. Threshold definitions for significant change on the timed 25-foot walk and nine-hole peg test in primary progressive multiple sclerosis. Koch MW; Repovic P; Mostert J; Bowen JD; Comtois J; Strijbis E; Uitdehaag B; Cutter G Eur J Neurol; 2023 Sep; 30(9):2761-2768. PubMed ID: 37306560 [TBL] [Abstract][Full Text] [Related]
2. A comparison of clinical outcomes in PPMS in the INFORMS original trial data set. Koch MW; Mostert JP; Uitdehaag B; Cutter G Mult Scler; 2021 Oct; 27(12):1864-1874. PubMed ID: 33464149 [TBL] [Abstract][Full Text] [Related]
3. The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset. Koch MW; Mostert J; Repovic P; Bowen JD; Comtois J; Strijbis E; Uitdehaag B; Cutter G J Neurol; 2022 Oct; 269(10):5319-5327. PubMed ID: 35570237 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis. Koch MW; Mostert JP; Wolinsky JS; Lublin FD; Uitdehaag B; Cutter GR Neurology; 2021 Oct; 97(16):e1560-e1570. PubMed ID: 34433679 [TBL] [Abstract][Full Text] [Related]
5. Clinical outcome measures in SPMS trials: An analysis of the IMPACT and ASCEND original trial data sets. Koch MW; Mostert J; Uitdehaag B; Cutter G Mult Scler; 2020 Oct; 26(12):1540-1549. PubMed ID: 31517591 [TBL] [Abstract][Full Text] [Related]
6. The nine hole peg test as an outcome measure in progressive MS trials. Koch MW; Repovic P; Mostert J; Bowen JD; Comtois J; Strijbis E; Uitdehaag B; Cutter G Mult Scler Relat Disord; 2023 Jan; 69():104433. PubMed ID: 36462470 [TBL] [Abstract][Full Text] [Related]
7. Impact of clinical outcomes and imaging measures on health-related quality of life in secondary progressive MS. W Koch M; Mostert J; Repovic P; Bowen JD; Strijbis E; Uitdehaag B; Cutter G Mult Scler; 2022 Jul; 28(8):1286-1298. PubMed ID: 34965774 [TBL] [Abstract][Full Text] [Related]
8. The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. Cadavid D; Cohen JA; Freedman MS; Goldman MD; Hartung HP; Havrdova E; Jeffery D; Kapoor R; Miller A; Sellebjerg F; Kinch D; Lee S; Shang S; Mikol D Mult Scler; 2017 Jan; 23(1):94-105. PubMed ID: 27003945 [TBL] [Abstract][Full Text] [Related]
9. An enrichment strategy for clinical trials in SPMS. Koch MW; Metz L; Cutter G Mult Scler; 2021 Oct; 27(12):1884-1893. PubMed ID: 33404355 [TBL] [Abstract][Full Text] [Related]
13. Distribution and relation of two arm function tests, Box and Blocks test and Nine Hole Peg test, across disease severity levels and types of multiple sclerosis. Bertoni R; Cattaneo D; Grosso C; Baglio F; Jonsdottir J Mult Scler Relat Disord; 2022 Mar; 59():103683. PubMed ID: 35168094 [TBL] [Abstract][Full Text] [Related]
14. The search for responsive clinical endpoints in primary progressive multiple sclerosis. Bosma LV; Kragt JJ; Brieva L; Khaleeli Z; Montalban X; Polman CH; Thompson AJ; Tintoré M; Uitdehaag BM Mult Scler; 2009 Jun; 15(6):715-20. PubMed ID: 19383646 [TBL] [Abstract][Full Text] [Related]
15. Brain grey matter perfusion in primary progressive multiple sclerosis: Mild decrease over years and regional associations with cognition and hand function. Testud B; Delacour C; El Ahmadi AA; Brun G; Girard N; Duhamel G; Heesen C; Häußler V; Thaler C; Has Silemek AC; Stellmann JP Eur J Neurol; 2022 Jun; 29(6):1741-1752. PubMed ID: 35167161 [TBL] [Abstract][Full Text] [Related]
16. Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis. Koch MW; Mostert J; Repovic P; Bowen JD; Uitdehaag B; Cutter G Neurology; 2021 Jan; 96(1):e111-e120. PubMed ID: 33106389 [TBL] [Abstract][Full Text] [Related]
17. Smoking, obesity, and disability worsening in PPMS: an analysis of the INFORMS original trial dataset. Koch MW; Mostert J; Repovic P; Bowen JD; Strijbis E; Uitdehaag B; Cutter G J Neurol; 2022 Mar; 269(3):1663-1669. PubMed ID: 34392376 [TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442 [TBL] [Abstract][Full Text] [Related]
19. Detecting clinically-relevant changes in progressive multiple sclerosis. Bosma LV; Sonder JM; Kragt JJ; Polman CH; Uitdehaag BM Mult Scler; 2015 Feb; 21(2):171-9. PubMed ID: 25013153 [TBL] [Abstract][Full Text] [Related]
20. The timed 25-foot walk in a large cohort of multiple sclerosis patients. Kalinowski A; Cutter G; Bozinov N; Hinman JA; Hittle M; Motl R; Odden M; Nelson LM Mult Scler; 2022 Feb; 28(2):289-299. PubMed ID: 34100297 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]